مقالات پذیرفته شده در سومین کنگره بین المللی زیست پزشکی
evaluation of Inducible nitric oxide synthase mRNA level as a blood-based biomarkers of inflammatory bowel disease .
evaluation of Inducible nitric oxide synthase mRNA level as a blood-based biomarkers of inflammatory bowel disease .
Saeed baranipour,1Tayebeh Azramezani kopi,2Azade Amini Kadijani,3,* Hamid Asadzadeh Aghdaei,4Shabnam Shahrokh,5
1. Student Research Committee, Babol University of Medical Sciences, Babol, Iran 2. Student Research Committee, Babol University of Medical Sciences, Babol, Iran 3. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti university of medical sciences, Tehran, Iran 4. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti university of medical sciences, Tehran, Iran 5. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti university of medical sciences, Tehran, Iran
Introduction: Non-invasive biomarkers of inflammatory bowel diseases (IBD) are of critical importance. Here, we evaluated the role of (iNOS) as a blood-based biomarker of inflammatory bowel diseases (IBD).
Up-regulation of inducible nitric oxide synthase (iNOS) in the intestinal epithelial cells has been closely associated with the initiation and maintenance of intestinal inflammation in IBD.
Methods: In a case-control design, 30 IBD patients and 30 healthy control subjects were participated in this study. A total of 10ml blood sample was taken from each participant. Blood leukocytes were isolated and iNOS mRNA expression level was evaluated in the isolated leukocytes using relative quantitative Real-time PCR
Results: The patients’ population included 20 ulcerative colitis (UC) and 10 Crohn's disease (CD) patients.The mean iNOS mRNA expression was significantly different between the IBD patients and healthy controls (p=0.01).
iNOS mRNA distinguished IBD patients from controls with the sensitivity and specificity of 66% and 64%, (p =0.002).
Conclusion: iNOS is differently expressed in the blood leukocytes of IBD patients vs healthy controls. Thus, it could be potentially used as a non-invasive blood-based biomarker of IBD.